Compare OFG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFG | PHVS |
|---|---|---|
| Founded | 1964 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2012 | 2020 |
| Metric | OFG | PHVS |
|---|---|---|
| Price | $52.89 | $34.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $45.17 | $41.82 |
| AVG Volume (30 Days) | 291.7K | ★ 393.4K |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 8.27 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.56 | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | $41.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.71 | $19.56 |
| 52 Week High | $53.82 | $36.60 |
| Indicator | OFG | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 54.09 |
| Support Level | $44.15 | $24.73 |
| Resistance Level | N/A | $36.07 |
| Average True Range (ATR) | 1.02 | 1.53 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 77.01 | 65.19 |
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.